1315 Capital and Ampersand Capital Partners Invest $20M in Interpace Biosciences

Interpace Biosciences entered into an agreement for a $20 million Series B Preferred Stock investment — $19 million from 1315 Capital and $1 million from existing investor Ampersand Capital Partners. The financing (and a coincident one-for-ten reverse stock split) is intended to help Interpace reach cash-flow break-even, accelerate growth and pursue acquisitions; Ampersand also exchanged its Series A preferred for the new Series B shares.